Latest Decheng Capital LLC Stock Portfolio
$661Million– No. of Holdings #14
Decheng Capital LLC Performance:
2026 Q1: -6.14%YTD: -6.14%2025: 68.98%
Performance for 2026 Q1 is -6.14%, and YTD is -6.14%, and 2025 is 68.98%.
About Decheng Capital LLC and 13F Hedge Fund Stock Holdings
On 2026-05-13, the fund reported it's updated stock portfolio. In the 13F Holdings report, Decheng Capital LLC reported an equity portfolio of $661.3 Millions as of 31 Mar, 2026.
The top stock holdings of Decheng Capital LLC are , NUVB, . The fund has invested 65.2% of it's portfolio in CG ONCOLOGY INC and 16.8% of portfolio in NUVATION BIO INC.
The fund managers got completely rid off CRINETICS PHARMACEUTICALS IN (CRNX), AURA BIOSCIENCES, INC. (AURA) and 4D MOLECULAR THERAPEUTICS IN (FDMT) stocks. They significantly reduced their stock positions in KRYSTAL BIOTECH INC (KRYS), REVOLUTION MEDICINES INC(NSM) (RVMD) and NEWAMSTERDAM PHARMA CO NV (NAMS).
The top stock holdings of Decheng Capital LLC are , NUVB, . The fund has invested 65.2% of it's portfolio in CG ONCOLOGY INC and 16.8% of portfolio in NUVATION BIO INC.
The fund managers got completely rid off CRINETICS PHARMACEUTICALS IN (CRNX), AURA BIOSCIENCES, INC. (AURA) and 4D MOLECULAR THERAPEUTICS IN (FDMT) stocks. They significantly reduced their stock positions in KRYSTAL BIOTECH INC (KRYS), REVOLUTION MEDICINES INC(NSM) (RVMD) and NEWAMSTERDAM PHARMA CO NV (NAMS).
Decheng Capital LLC Equity Portfolio Value
Last Reported on: 13 May, 2026
Decheng Capital LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Decheng Capital LLC made a return of -6.14% in the last quarter. In trailing 12 months, it's portfolio return was 107.98%.
- Performance
- S&P 500
New Buys
Additions
Reductions
| Ticker | % Reduced |
|---|---|
| krystal biotech inc | -57.8 |
| revolution medicines inc(nsm) | -53.25 |
| newamsterdam pharma co nv | -45.1 |
| upstream bio inc. | -13.31 |
| arcus biosciences, inc | -11.77 |
Decheng Capital LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| nuvation bio inc. | -213,198 |
| aura biosciences, inc. | -1,964,630 |
| crinetics pharmaceuticals in | -4,315,180 |
| rezolute inc | -141,364 |
| 4d molecular therapeutics in | -332,333 |
Decheng Capital LLC got rid off the above stocks
Sector Distribution
Decheng Capital LLC has about 73.7% of it's holdings in Others sector.
- Others
- Healthcare
| Sector | % |
|---|---|
| Others | 73.7 |
| Healthcare | 26.3 |
Market Cap. Distribution
Decheng Capital LLC has about 1.4% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- SMALL-CAP
- MICRO-CAP
- MID-CAP
- LARGE-CAP
| Category | % |
|---|---|
| UNALLOCATED | 73.7 |
| SMALL-CAP | 21.2 |
| MICRO-CAP | 1.9 |
| MID-CAP | 1.8 |
| LARGE-CAP | 1.4 |
Stocks belong to which Index?
About 24.9% of the stocks held by Decheng Capital LLC either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 75.1 |
| RUSSELL 2000 | 24.9 |
Decheng Capital LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Decheng Capital LLC
Decheng Capital LLC has 14 stocks in it's portfolio. About 98.2% of the portfolio is in top 10 stocks. NUVB proved to be the most loss making stock for the portfolio. was the most profitable stock for Decheng Capital LLC last quarter.
Last Reported on: 13 May, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACRS | aclaris therapeutics, inc. | 2.29 | 4,041,740 | 15,156,500 | unchanged | 0.00 | ||
| AURA | aura biosciences, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BYSI | beyondspring inc. | 0.94 | 3,800,700 | 6,233,150 | unchanged | 0.00 | ||
| CRNX | crinetics pharmaceuticals in | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| EQ | equillium inc. | 1.34 | 4,447,310 | 8,894,620 | unchanged | 0.00 | ||
| FDMT | 4d molecular therapeutics in | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| KRYS | krystal biotech inc | 0.28 | 7,300 | 1,885,740 | reduced | -57.8 | ||
| LYEL | lyell immunopharma, inc. | 2.10 | 692,050 | 13,882,500 | unchanged | 0.00 | ||
| NAMS | newamsterdam pharma co nv | 1.57 | 325,057 | 10,405,100 | reduced | -45.1 | ||
| NUVB | nuvation bio inc. | 16.84 | 25,954,400 | 111,345,000 | unchanged | 0.00 | ||
| NUVB | nuvation bio inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| PYXS | pyxis oncology, inc (formerly apexigen) | 0.07 | 326,810 | 477,143 | unchanged | 0.00 | ||
| RCUS | arcus biosciences, inc | 1.56 | 477,819 | 10,320,900 | reduced | -11.77 | ||
| RVMD | revolution medicines inc(nsm) | 1.38 | 93,500 | 9,092,880 | reduced | -53.25 | ||
| RZLT | rezolute inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ZNTL | zentalis pharmaceuticals inc. | 0.47 | 1,323,330 | 3,096,580 | unchanged | 0.00 | ||
| cg oncology inc | 65.21 | 6,371,670 | 431,235,000 | unchanged | 0.00 | |||
| upstream bio inc. | 3.71 | 2,724,870 | 24,523,800 | reduced | -13.31 | |||
| aardvark therapeutics inc | 2.23 | 3,917,300 | 14,768,200 | unchanged | 0.00 | |||